Payments the buyer put on record
Across 40 selected transactions from China, Taiwan, Japan and South Korea, buyers verified US$3.7145 billion in upfront cash on 14 rows by the cutoff. This is a subtotal of individually identifiable payments. It includes the upfront cash component of completed deals disclosed by the payer and cash explicitly reported as paid. Other categories stay in their own fields. Madrigal reports US$4 million paid on a later Ribocure nomination milestone. CSPC reports receipt of a separate US$25 million development milestone. The coverage is a purposive sample of publicly documented deals and several separately announced amendments. It supports direct comparisons of individual agreements. Differences in filing access, disclosure and agreement timing limit country-level comparisons. [D00] [D99] [D15P] [D01R]

CSPC–AstraZeneca and Innovent–Pfizer account for US$1.2 billion and US$650 million, respectively, of verified upfront cash. Pfizer placed its Innovent payment in operating cash flow. The Hengrui–BMS filing gives another clean cash-to-accrual comparison. BMS paid US$600 million and recorded a US$175 million noncancellable first-anniversary payment in the same quarter. That latter obligation is payable in 2027. The signed package also includes a conditional second-anniversary payment of US$175 million. [D01P] [D03P] [D04] [D04P] [D04X]
The cash column reflects the evidence available at the cutoff. A payment can move into that group as soon as a payer identifies the disbursement in a later filing. SciBrunch illustrates why timing matters. Merck closed the global license for SPR2015 in September and recorded US$400 million in research and development expense, with the actual payment expected in the fourth quarter. AbbVie recorded a US$650 million upfront charge for RemeGen’s RC148. The asset-specific note identifies the expense and agreement. RemeGen separately reported receipt of the full US$650 million in April. The verified subtotal uses the payer-side cash rule and the receipt is visible in its own column. [D07] [D07P] [D02P] [D02R]
The headline buys a different thing in each agreement
AstraZeneca’s CSPC agreement combines rights outside mainland China, Hong Kong, Macau and Taiwan for the initial portfolio, work on more programs, and an option to co-commercialize in China. Its US$18.5 billion arithmetic maximum before royalties comprises US$1.2 billion upfront, up to US$3.5 billion in development-related payments and up to US$13.8 billion tied to sales. Pfizer’s Innovent package combines a US$650 million cash upfront and up to US$9.85 billion in milestones. Profit sharing applies to designated jointly developed and commercialized programs in the United States and Europe. RemeGen’s publicly announced US$650 million plus US$4.95 billion in milestones concerns a single named antibody, RC148, licensed outside Greater China. The AbbVie filing presents the contingent figure rounded to US$5.0 billion. [D01] [D01P] [D02] [D02X] [D03] [D03P]

The percentages are easy to compute and easy to misread. A portfolio maximum can attach downstream payments to many programs and indications. A collaborator needs to determine which options are exercisable, which party funds development, and what local rights the originator keeps. BMS and Hengrui bundled outbound Hengrui assets, inbound BMS assets and discovery options into their approximately US$15.2 billion potential package. Allocating that headline to a single outbound asset would assign economics the companies never disclosed. [D04] [D04X]
Dizal offers a second accounting distinction. AstraZeneca reported US$600 million in upfront cash consideration for Zegfrovy after closing. The contract announcement allowed up to US$900 million in contingent payments. The acquisition accounting estimated those contingent payments at US$346 million of provisional fair value, for US$946 million of provisional consideration. The contractual maximum describes possible obligations. Acquisition-date fair value is the amount recognized on a different basis. [D05] [D05P] [D05X]

Rights follow the contract
Start with development, manufacturing and commercial rights, then read them by territory. The SEC filing places Biogen’s US$100 million felzartamab upfront in the verified cash column. Its rights cover Greater China and involve legacy obligations to MorphoSys. Travere paid US$112.5 million in July for civorebrutinib rights outside China and selected East and Southeast Asian markets. The partners share costs for specified global clinical development. These two China-origin rows capture materially different rights and retain separate geographic labels. [D11] [D11P] [D12] [D12P]

Japan and South Korea also show why the form of the payment matters. Mineralys paid Tanabe US$200 million to amend the existing lorundrostat license and extinguish future royalties. Its new commercial milestones extend to US$100 million, while the broader US$265 million remaining milestone exposure includes obligations that survived the amendment. Senju’s KIO-401 contract calls for US$3.5 million upfront and a US$12.5 million technology-transfer milestone, some of which may be credited against later obligations. Agios confirms a US$25 million upfront cash outflow for cevidoplenib, with Oscotec’s South Korean opt-in preserved. Biogen’s US$20 million Alteogen payment closed a delivery-platform license for subcutaneous biologics. A conditional US$10 million for starting development of the second product sits outside upfront. [D19] [D19X] [D22] [D22P] [D28] [D28P] [D29] [D29P]
An equity clause requires its own entry. Avere’s prospectus confirms US$90 million paid to Hansoh toward a contractual US$120 million upfront, with the US$30 million balance tied to completion of a qualifying reverse merger. It also records preferred shares issued in connection with the agreement. The separate financing has a different purpose and no part of the preferred shares is counted in the cash subtotal. Tanabe’s Tolerance Bio agreement includes equity consideration whose value was undisclosed. [D18] [D18P] [D18X] [D20]
Taiwan pairs platform licenses with local routes to market
OBI Pharma’s Novartis agreement sets out US$30 million upfront and a total potential value above US$2 billion. Novartis receives exclusive worldwide rights to relevant OBI ADC platform technology, patents and know-how for specified, undisclosed payloads. The originator disclosed the terms in November. A payer report confirming the cash transfer was unavailable at the cutoff. Calling the upfront a receipt would change what the record establishes. [D40] [D40X]

Foresee’s US$10 million Primevera upfront comes with a retained 19% equity interest and a choice of economic paths. Under the direct-commercialization terms in the shareholder circular, regulatory and sales milestones total as much as US$574.5 million. Adding the upfront gives US$584.5 million before royalties. The English release’s summary applies that combined number to milestones, while its body matches the circular’s components. The circular’s alternative proceeds split applies if Primevera sublicenses. Foresee’s interim cash-flow statement records the upfront as cash proceeds and the related-party note values the 19% interest at US$7.79 million at initial recognition. [D39] [D39X] [D39R]
TLC granted Japan rights to TLC599 with a combined package as high as US$203 million. The filing gives the signing fee and milestones a common ceiling and leaves the signing fee itself undisclosed. Formosa’s APP13007 appears three times, each covering a distinct authorized market. Its agreements give Samil South Korea and Vietnam commercialization rights and Arrotex Australia and New Zealand commercialization rights. TaiGen’s Pixavir license and Anxo’s extended-release tamsulosin also give local partners South Korean development and commercialization rights. These regional deals show Taiwan-origin drugs reaching distinct local channels even when neither party gives a standalone upfront number. [D32] [D33] [D35] [D36] [D37] [D38]
Three judgments to carry into the next reporting cycle
The verified subtotal will change when more payers identify their disbursements. Look for a cash statement or a completed acquisition disclosure that names the upfront cash amount. Keep agreed payments and expense entries visible so readers can tell which 2026 contracts have moved into cash. Merck’s US$400 million SciBrunch obligation is an immediate test of the rule. [D07P] [D99]
The strongest comparison pairs the upfront with the width of the rights. Portfolio options, territorial carve-outs and shared commercialization can change what a buyer acquired more than the headline amount changes. The BMS–Hengrui portfolio, AstraZeneca’s CSPC collaboration and Biogen’s Greater China license assign decision-making and development costs differently. [D01] [D04] [D11]
Taiwan has two observable licensing paths in this sample. OBI and Foresee offer platform or program rights with meaningful published upfronts. Formosa and TLC show how territorial partners can carry commercialization, launch or development market by market. The next test for the November OBI agreement is a payer disclosure that identifies when the upfront was paid. [D32] [D35] [D36] [D38] [D39] [D40]

Transaction ledger
Amounts in US$ millions. A blank in the download or “Not disclosed” in the table marks an undisclosed or unverified value. Standalone upfront and confirmed paid columns use separate fields. Package references may include signing consideration and contingent payments. They exclude separately described royalties unless the underlying document explicitly says otherwise. Rows with different document dates preserve both the announcement date and the source publication date. Download the transaction CSV.
| Announced | Origin | Licensor → buyer / asset | Rights | Agreed upfront | Payer verified | Licensor receipt | Follow-on / equity | Evidence |
|---|---|---|---|---|---|---|---|---|
| 2026-01-30 | China | CSPC → AstraZeneca / Cardiometabolic portfolio | Exclusive outside mainland China, Hong Kong, Macau and Taiwan; China co-commercialization option | 1200 | 1200 | 1200 | Development and regulatory up to $3.5bn and sales up to $13.8bn; royalties separate / Milestone ref. 17300 / Package ref. 18500 | [D01] [D01P] [D01R] |
| 2026-01-12 | China | RemeGen → AbbVie / RC148 | Exclusive worldwide excluding Greater China; development, manufacturing and commercialization | 650 | Unverified | 650 | Development, regulatory and commercial; tiered double-digit royalties separate / Milestone ref. 4950 / Package ref. 5600 | [D02] [D02P] [D02R] |
| 2026-05-28 | China | Innovent → Pfizer / Oncology portfolio | Program-level global development and licensing; U.S. and European profit share on co-developed and co-commercialized programs | 650 | 650 | — | Development, regulatory and commercial; royalties or profit share as applicable / Milestone ref. 9850 / Package ref. 10500 | [D03] [D03P] |
| 2026-05-12 | China | Hengrui → Bristol Myers Squibb / Oncology, hematology and immunology portfolio | BMS obtains Hengrui-originated rights outside mainland China, Hong Kong and Macau; package also has inbound BMS programs | 600 | 600 | — | $175m first anniversary and $175m second anniversary contingent; development, regulatory and commercial milestones separate / Package ref. 15200 | [D04] [D04P] |
| 2026-07-14 | China | Dizal → AstraZeneca / Zegfrovy / sunvozertinib | Worldwide development and commercialization; closed transfer also included staff and contracts supporting China manufacturing | 600 | 600 | — | Development, regulatory and sales; tiered royalties separate / Milestone ref. 900 / Package ref. 1500 | [D05] [D05P] |
| 2026-10-02 | China | Abogen → Novartis / ABO2203 and RNA programs | Worldwide lead-asset license plus options over other RNA programs | 575 | Unverified | — | Approximate milestone maximum requires exercise of all options plus milestone achievement; royalties separate / Milestone ref. 7200 | [D06] |
| 2026-09-28 | China | SciBrunch → Merck / SPR2015 / MK-2690 | Exclusive global development, manufacture and commercialization | 400 | Unverified | — | Multi-indication contingent milestones; payer expected the upfront to be paid in Q4 / Milestone ref. 1730 / Package ref. 2130 | [D07] [D07P] |
| 2026-10-19 | China | Hansoh → Roche / ADC programs | Worldwide outside Greater China; Hansoh options for selected programs and possible U.S. participation | 400 | Unverified | — | $110m first anniversary plus more than $15bn in potential milestones; royalties separate | [D08] |
| 2026-02-08 | China | Innovent → Eli Lilly / Oncology and immunology collaboration | Lilly leads most programs outside Greater China; separate U.S. commercial participation for designated programs | 350 | Unverified | — | Future development, regulatory and commercial milestones; royalties separate / Milestone ref. 8500 | [D09] |
| 2026-09-29 | China | Hengrui → Novo Nordisk / HRS-1596 | Exclusive worldwide excluding Greater China | 300 | Unverified | — | Development, regulatory and commercial milestones; royalties separate / Milestone ref. 2300 / Package ref. 2600 | [D10] |
| 2026-04-20 | China | TJ Biopharma → Biogen / Felzartamab | Exclusive Greater China rights acquired under asset purchase agreement | 100 | 100 | — | Commercial $20m and sales $730m maximum; separate legacy MorphoSys obligations / Milestone ref. 750 / Package ref. 850 | [D11] [D11P] |
| 2026-06-02 | China | Everest Medicines → Travere / Civorebrutinib / EVER001 | Exclusive outside China and selected East and Southeast Asian markets; global trial costs shared | 112.5 | 112.5 | — | Payer filing rounds additional milestones to about $1bn; tiered royalties separate / Milestone ref. 1000 | [D12] [D12P] |
| 2026-07-14 | China | Innovent → Spero / SP001 / IBI355 | Worldwide excluding Greater China; defined research/manufacturing carve-outs for Innovent | 35 | 35 | — | Development, regulatory and commercial; royalties separate / Milestone ref. 1050 | [D13] [D13P] |
| 2026-06-22 | China | Haisco → Nuvectis / NXP100 / NXP200 | Exclusive worldwide excluding mainland China, Hong Kong, Macau and Taiwan | 20 | 20 | — | Approximately $1.4bn in potential milestones for both programs; royalties separate / Milestone ref. 1400 | [D14] [D14P] |
| 2026-02-11 | China | Suzhou Ribo / Ribocure → Madrigal / MASH siRNA programs | Worldwide exclusive development, manufacture and commercialization of licensed programs | 60 | 60 | — | Payer-reported $4m already paid on candidate nomination; full contingent cap as reported by the payer / Milestone ref. 4400 | [D15] [D15P] |
| 2026-01-12 | China | Nanjing Hanxin → Amphastar / AMP-110 | Exclusive U.S. and Canadian rights to the licensed ACTH product, subject to contract | 2 | 2 | — | Development up to $14m and sales up to $75m; royalty cap separately specified / Milestone ref. 89 | [D16] [D16P] |
| 2026-09-03 | China | HUTCHMED → GSK / HMPL-A830 | Worldwide excluding mainland China, Hong Kong, Macau and Taiwan; earlier asset has a first negotiation right | 110 | Unverified | — | Development, regulatory and commercial; tiered royalties separate / Milestone ref. 1185 / Package ref. 1295 | [D17] |
| 2026-07-14 | China | Hansoh → Avere / AVR-001 / HS-20118 | Worldwide exclusive outside Greater China | 120 | 90 | — | $90m within contractual window and $30m upon qualified reverse merger; separate milestones and royalties / 15,291,667 Seed-1 preferred shares issued | [D18] [D18P] |
| 2026-10-29 | Japan | Senju → Kiora / KIO-401 | Exclusive in the Americas, Europe, Middle East and Africa | 3.5 | Unverified | — | $12.5m technology transfer, partly creditable, and up to $168.5m in regulatory and commercial milestones / Milestone ref. 168.5 | [D19] [D19P] |
| 2026-09-28 | Japan | Tanabe → Tolerance Bio / TLB-33 / MT-2990 | Worldwide development and manufacture; commercialization outside Japan | Not disclosed | Unverified | — | Approximate development and sales milestone maximum; royalties separate / equity consideration, value undisclosed / Milestone ref. 560 | [D20] |
| 2026-08-18 | Japan | Tanabe → LEO Pharma / Dersimelagon / MT-7117 | Transfer of global rights for EPP and XLP, including development and commercialization | Not disclosed | Unverified | — | Up to $435m combined upfront and near-term milestones; downstream milestones and royalties extra | [D21] |
| 2026-06-03 | Japan | Tanabe → Mineralys / Lorundrostat | Existing license amendment; modified scope and royalty extinguishment | 200 | 200 | — | Up to $100m new sales milestones; $265m aggregate remaining milestones include surviving original obligations / Milestone ref. 100 | [D22] [D22P] |
| 2026-04-10 | Japan | SCOHIA → Neurocrine / SCO-483 | Exclusive worldwide development and commercialization | 20 | Unverified | 20 | Development and commercial milestones; royalties separate / Milestone ref. 550 | [D23] [D23R] |
| 2026-01-07 | Japan | Daiichi Sankyo → GENESIS Pharma / Quizartinib | Commercialization in specified Central and Eastern European markets; supply remains with Daiichi | Not disclosed | Unverified | — | Not disclosed | [D24] |
| 2026-10-29 | South Korea | GC Biopharma / Hanmi → BioMarin / HM15421 / GC1134A | Exclusive worldwide development and commercialization; subject to disclosed arrangements | 70 | Unverified | — | Development, regulatory and commercial milestones; royalties separate | [D25] |
| 2026-10-14 | South Korea | PinotBio → Alentis / ADC linker and payload technology | Exclusive option to license selected linkers and/or payloads for development candidates | Not disclosed | Unverified | — | Upfront and milestones disclosed without amounts; royalties on elected candidates | [D26] |
| 2026-08-24 | South Korea | Hanmi → Genentech / HM17321 | Exclusive worldwide outside South Korea; Genentech assumes development after Hanmi’s dose-escalation work | 190 | Unverified | — | Company release quotes about $2.3bn, with inconsistent royalty inclusion across summary and body | [D27] |
| 2026-06-01 | South Korea | Oscotec / Genosco → Agios / Cevidoplenib | Global rights subject to Oscotec opt-in in South Korea | 25 | 25 | — | Payer lists $140m U.S./EU development and regulatory milestones plus sales milestones; licensor announced the package cap / Package ref. 665 | [D28] [D28P] |
| 2026-03-25 | South Korea | Alteogen → Biogen / ALT-B4 / Hybrozyme | License for subcutaneous versions of selected biologics | 20 | 20 | — | $10m conditional on second-product development initiation; additional milestones and royalties separate / Milestone ref. 549 | [D29] [D29P] |
| 2026-03-24 | South Korea | Oscotec → Yatiri / Denfivontinib | Exclusive option to in-license for acute myeloid leukemia | Not disclosed | Unverified | — | Not disclosed | [D30] |
| 2026-01-09 | South Korea | Prazer → Janssen / SPiDEM degrader platform | Research and licensing collaboration over selected targets | Not disclosed | Unverified | — | Not disclosed | [D31] |
| 2026-10-05 | Taiwan | TLC BioSciences → Nippon Zoki / TLC599 | Exclusive development and commercialization in Japan | Not disclosed | Unverified | — | Combined signing fee and development, regulatory and sales milestones; tiered royalties separate / Package ref. 203 | [D32] |
| 2026-09-16 | Taiwan | Anxo → YS Life Science / Extended-release tamsulosin ODT | Exclusive development and sale in South Korea | Not disclosed | Unverified | — | Not disclosed | [D33] |
| 2026-08-10 | Taiwan | Lumosa → AMED Co., Ltd. / LT1001 | Regional amendment adding UAE, Saudi Arabia, Kuwait, Oman, Qatar and Bahrain | Not disclosed | Unverified | — | Milestones and royalties depend on registration and sales; amounts not disclosed | [D34] |
| 2026-06-11 | Taiwan | Formosa Pharmaceuticals → Samil / APP13007 | Exclusive commercialization in Vietnam | Not disclosed | Unverified | — | Upfront, regulatory and sales milestones, and royalties; amounts not disclosed | [D35] |
| 2026-02-23 | Taiwan | Formosa Pharmaceuticals → Arrotex / APP13007 | Exclusive commercialization in Australia and New Zealand | Not disclosed | Unverified | — | Upfront, regulatory and sales milestones, and royalties; amounts not disclosed | [D36] |
| 2026-01-26 | Taiwan | TaiGen → Boryung Biopharma / Pixavir marboxil / TG-1000 | Exclusive development and marketing in South Korea | Not disclosed | Unverified | — | Upfront, milestones and royalties; amounts not disclosed | [D37] |
| 2026-01-12 | Taiwan | Formosa Pharmaceuticals → Samil / APP13007 | Exclusive commercialization in South Korea | Not disclosed | Unverified | — | Upfront, regulatory and sales milestones, and royalties; amounts not disclosed | [D38] |
| 2026-01-08 | Taiwan | Foresee → Primevera / MMP-12 inhibitor programs | Exclusive global license for the licensed programs | 10 | Unverified | 10 | Up to $574.5m milestones under direct commercialization; alternate sublicense proceeds mechanism may replace milestones and royalties / 19% stake, initially valued at US$7.79m / Milestone ref. 574.5 / Package ref. 584.5 | [D39] [D39R] |
| 2026-11-13 | Taiwan | OBI Pharma → Novartis / ADC platform | Worldwide exclusive license to relevant technology, patents and know-how for specified undisclosed payloads | 30 | Unverified | — | Potential total exceeds $2bn, with development, regulatory and commercial milestones | [D40] |
Coverage and corrections
The ledger covers selected agreements publicly announced between January and the cutoff. The country denotes the originator used for deal attribution, independent of payer location. Named sponsor origin and deal direction are recorded independently of territory. Hong Kong-origin or mainland/Hong Kong groups appear in the China group with the specific company named. Region expansions, option-only agreements and changes to an existing license are labeled in the download. The ledger counts each agreement package once, even when more than one asset or licensor is named. A letter of intent without a specified rights agreement is outside this set.
For corrections, supply the named agreement, the primary document, publication date and the clause or financial note that changes the amount, territory or payment status. General research only. This report does not provide investment or medical advice.
Frequently asked questions
How much upfront cash did Asia-origin biotech licensors receive in 2026, based on buyer filings?
Across 40 selected transactions from China, Taiwan, Japan and South Korea, buyers verified US$3.7145 billion in upfront cash on 14 rows by the cutoff. This is a subtotal of individually identifiable payments. It includes the upfront cash component of completed deals disclosed by the payer and cash explicitly reported as paid. Other categories stay in their own fields. Madrigal reports US$4 million paid on a later Ribocure nomination milestone. CSPC reports receipt of a separate US$25 million development milestone. The coverage is a purposive sample of publicly documented deals and several separately announced amendments. It supports direct comparisons of individual agreements. Differences in filing access, disclosure and agreement timing limit country-level comparisons. [D00] [D99] [D15P] [D01R]
Does Merck’s US$400 million SciBrunch expense mean it had already paid cash?
The cash column reflects the evidence available at the cutoff. A payment can move into that group as soon as a payer identifies the disbursement in a later filing. SciBrunch illustrates why timing matters. Merck closed the global license for SPR2015 in September and recorded US$400 million in research and development expense, with the actual payment expected in the fourth quarter. AbbVie recorded a US$650 million upfront charge for RemeGen’s RC148. The asset-specific note identifies the expense and agreement. RemeGen separately reported receipt of the full US$650 million in April. The verified subtotal uses the payer-side cash rule and the receipt is visible in its own column. [D07] [D07P] [D02P] [D02R]
Why do the CSPC–AstraZeneca, Innovent–Pfizer and RemeGen–AbbVie deal headlines differ?
AstraZeneca’s CSPC agreement combines rights outside mainland China, Hong Kong, Macau and Taiwan for the initial portfolio, work on more programs, and an option to co-commercialize in China. Its US$18.5 billion arithmetic maximum before royalties comprises US$1.2 billion upfront, up to US$3.5 billion in development-related payments and up to US$13.8 billion tied to sales. Pfizer’s Innovent package combines a US$650 million cash upfront and up to US$9.85 billion in milestones. Profit sharing applies to designated jointly developed and commercialized programs in the United States and Europe. RemeGen’s publicly announced US$650 million plus US$4.95 billion in milestones concerns a single named antibody, RC148, licensed outside Greater China. The AbbVie filing presents the contingent figure rounded to US$5.0 billion. [D01] [D01P] [D02] [D02X] [D03] [D03P]
What rights and upfront did OBI disclose in its Novartis deal?
OBI Pharma’s Novartis agreement sets out US$30 million upfront and a total potential value above US$2 billion. Novartis receives exclusive worldwide rights to relevant OBI ADC platform technology, patents and know-how for specified, undisclosed payloads. The originator disclosed the terms in November. A payer report confirming the cash transfer was unavailable at the cutoff. Calling the upfront a receipt would change what the record establishes. [D40] [D40X]
What did Foresee retain in its Primevera deal, and how large were the contingent payments?
Foresee’s US$10 million Primevera upfront comes with a retained 19% equity interest and a choice of economic paths. Under the direct-commercialization terms in the shareholder circular, regulatory and sales milestones total as much as US$574.5 million. Adding the upfront gives US$584.5 million before royalties. The English release’s summary applies that combined number to milestones, while its body matches the circular’s components. The circular’s alternative proceeds split applies if Primevera sublicenses. Foresee’s interim cash-flow statement records the upfront as cash proceeds and the related-party note values the 19% interest at US$7.79 million at initial recognition. [D39] [D39X] [D39R]
References
- D00
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (hkexnews.hk) | | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0130/2026013000101.pdf
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (news.abbvie.com) | | https://news.abbvie.com/2026-01-12-AbbVie-and-RemeGen-Announce-Exclusive-Licensing-Agreement-to-Develop-A-Novel-Bispecific-Antibody-for-Advanced-Solid-Tumors
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (pfizer.com) | | https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-innovent-biologics-enter-global-strategic
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (hengrui.com) | | https://www.hengrui.com/en/media/detail-951.html
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (abogenbio.com) | | https://www.abogenbio.com/news/company/news2026/277.html
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (merck.com) | | https://www.merck.com/news/merck-enters-into-exclusive-global-license-agreement-with-scibrunch-therapeutics-for-spr2015-an-investigational-oral-kras-g12d-on-inhibitor/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (hspharm.com) | | https://www.hspharm.com/news/news-detail-513518.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (prnewswire.com) | | https://www.prnewswire.com/news-releases/innovent-announces-strategic-collaboration-with-lilly-to-develop-new-medicines-globally-in-oncology-and-immunology-302682009.html
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (hengrui.com) | | https://www.hengrui.com/en/media/detail-1042.html
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260930.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/d320658d8k.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1875558/000110465926076624/tm2618439d1_8k.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1157601/000162828026069145/R18.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (nasdaq.com) | | https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-announces-exclusive-license-agreement-nanjing-hanxin
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor SEC exhibit (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1648257/000164825726000057/hcm-20260903xex99d1.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1661059/000110465926123934/tm2623032-12_424b3.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (ir.kiorapharma.com) | | https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000088/kprx-20261023.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (tolerancebio.com) | | https://www.tolerancebio.com/recent-news/tolerance-bio-licenses-clinical-stage-anti-il-33-monoclonal-antibody-from-tanabe-pharma-to-expand-thymus-focused-clinical-pipeline
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (us.tanabe-pharma.com) | | https://us.tanabe-pharma.com/news-and-media/press-releases/2026/tanabe-pharma-enters-into-agreement-with-leo-pharma-for-mt-7117-for-epp-and-xlp
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (ir.mineralystx.com) | | https://ir.mineralystx.com/sec-filings/all-sec-filings/content/0001628280-26-040024/mlys-20260602.htm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (scohia.com) | | https://www.scohia.com/eng/sys/news/260410en/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (genesispharma.com) | | https://www.genesispharma.com/newsroom/news/daiichi-sankyo-and-genesis-pharma-enter-exclusive-agreement-for-quizartinib-commercialization-in-central-eastern-europe/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (investors.biomarin.com) | | https://investors.biomarin.com/news/news-details/2026/BioMarin-Enters-Into-Exclusive-Worldwide-License-Agreement-With-GC-Biopharma-and-Hanmi-Pharm-for-Investigational-Next-Generation-Enzyme-Replacement-Therapy-Adding-a-Second-Potential-Treatment-for-Fabry-Disease/default.aspx
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (alentis.ch) | | https://alentis.ch/alentis-and-pinotbio-announce-collaboration-to-develop-next-generation-adcs-targeting-claudin-1/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (hanmipharm.com) | | https://www.hanmipharm.com/about/investor-relations/press/detail-4843.hm
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (oscotec.com) | | https://oscotec.com/archives/394656
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (en.prnasia.com) | | https://en.prnasia.com/releases/global/alteogen-enters-into-a-license-agreement-with-biogen-for-development-and-commercialization-of-hybrozyme-based-subcutaneous-biologics-526696.shtml
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | payer or joint release (yatiribio.com) | | https://yatiribio.com/2026/03/24/yatiri-bio-enters-exclusive-option-to-in-license-agreement-with-oscotec-for-denfivontinib-in-aml/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (prazertx.com) | | https://prazertx.com/pages/board/view.php?board_sid=16&category_code1=&data_sid=278&menu_code=477&page_num=&skey=&sval=
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (mopsov.twse.com.tw) | | https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=152833&spoke_date=20261005&co_id=7924&TYPEK=rotc
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (anxo.com.tw) | | https://www.anxo.com.tw/news/view/231
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (mopsov.twse.com.tw) | | https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=5&spoke_time=180917&spoke_date=20260810&co_id=6535&TYPEK=otc
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (formosapharma.com) | | https://www.formosapharma.com/%E5%8F%B0%E6%96%B0%E8%97%A5%E5%AE%A3%E5%B8%83%E8%88%87samil-pharmaceutical-%E7%B0%BD%E7%BD%B2%E6%8E%88%E6%AC%8A%E5%8D%94%E8%AD%B0%EF%BC%8C%E6%8E%A8%E5%8B%95%E7%9C%BC%E9%83%A8%E8%A1%93%E5%BE%8C/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (formosapharma.com) | | https://www.formosapharma.com/formosa-pharmaceuticals-announces-licensing-agreement-with-arrotex-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-sur/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (taigenbiotech.com) | | https://www.taigenbiotech.com/en/news/detail/226
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (formosapharma.com) | | https://www.formosapharma.com/formosa-pharmaceuticals-announces-licensing-agreement-with-samil-pharmaceuticals-co-ltd-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-p/
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (foreseepharma.com) | | https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_global_licensing_agreement_for_mmp_12_inhibitors_with_primevera_therapeutics_llc?page=1
- 40 selected rows; {'China': 18, 'Japan': 6, 'South Korea': 7, 'Taiwan': 9} | licensor disclosure (obipharma.com) | | https://www.obipharma.com/zh-hant/news/signs-collaboration-and-license-agreement-with-novartis/
- D01
- 2026-01-30 · Cardiometabolic portfolio | licensor disclosure (hkexnews.hk) | | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0130/2026013000101.pdf
- D01P
- Upfront paid US$m 1200; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm
- D01R
- Licensor confirms upfront receipt US$m 1200; other cash US$m 25 | licensor receipt (www1.hkexnews.hk) | | https://www1.hkexnews.hk/listedco/listconews/sehk/2026/1118/2026111800389.pdf
- D01X
- US$1.2bn received on May 29 | licensor exchange receipt (hkexnews.hk) | | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0529/2026052902358.pdf
- D02
- 2026-01-12 · RC148 | payer or joint release (news.abbvie.com) | | https://news.abbvie.com/2026-01-12-AbbVie-and-RemeGen-Announce-Exclusive-Licensing-Agreement-to-Develop-A-Novel-Bispecific-Antibody-for-Advanced-Solid-Tumors
- D02P
- Upfront paid US$m unverified; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm
- D02R
- Licensor confirms upfront receipt US$m 650; other cash US$m not specified | licensor receipt (hkexnews.hk) | | https://www.hkexnews.hk/listedco/listconews/sehk/2026/0415/2026041500526.pdf
- D02X
- US$650m recorded in Q1; US$5.0bn rounded contingent amount in the payer filing | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1551152/000155115226000026/abbv-20260630.htm
- D03
- 2026-05-28 · Oncology portfolio | payer or joint release (pfizer.com) | | https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-innovent-biologics-enter-global-strategic
- D03P
- Upfront paid US$m 650; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/pfe-20260927.htm
- D04
- 2026-05-12 · Oncology, hematology and immunology portfolio | licensor disclosure (hengrui.com) | | https://www.hengrui.com/en/media/detail-951.html
- D04P
- Upfront paid US$m 600; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/bmy-20260930.htm
- D04X
- US$600m paid; US$175m noncancellable anniversary payment for 2027 | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/bmy-20260930.htm
- D05
- 2026-07-14 · Zegfrovy / sunvozertinib | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm
- D05P
- Upfront paid US$m 600; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000165495426009256/a0835b.htm
- D05X
- US$946m provisional fair value: $600m upfront and $346m contingent fair value | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000165495426009256/a0835b.htm
- D06
- 2026-10-02 · ABO2203 and RNA programs | licensor disclosure (abogenbio.com) | | https://www.abogenbio.com/news/company/news2026/277.html
- D07
- 2026-09-28 · SPR2015 / MK-2690 | payer or joint release (merck.com) | | https://www.merck.com/news/merck-enters-into-exclusive-global-license-agreement-with-scibrunch-therapeutics-for-spr2015-an-investigational-oral-kras-g12d-on-inhibitor/
- D07P
- Upfront paid US$m unverified; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/mrk-20260930.htm
- D08
- 2026-10-19 · ADC programs | licensor disclosure (hspharm.com) | | https://www.hspharm.com/news/news-detail-513518.htm
- D09
- 2026-02-08 · Oncology and immunology collaboration | licensor disclosure (prnewswire.com) | | https://www.prnewswire.com/news-releases/innovent-announces-strategic-collaboration-with-lilly-to-develop-new-medicines-globally-in-oncology-and-immunology-302682009.html
- D10
- 2026-09-29 · HRS-1596 | licensor disclosure (hengrui.com) | | https://www.hengrui.com/en/media/detail-1042.html
- D11
- 2026-04-20 · Felzartamab | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260930.htm
- D11P
- Upfront paid US$m 100; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260930.htm
- D12
- 2026-06-02 · Civorebrutinib / EVER001 | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm
- D12P
- Upfront paid US$m 112.5; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm
- D13
- 2026-07-14 · SP001 / IBI355 | payer or joint release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1701108/000119312526302473/d320658d8k.htm
- D13P
- Upfront paid US$m 35; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm
- D14
- 2026-06-22 · NXP100 / NXP200 | payer or joint release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1875558/000110465926076624/tm2618439d1_8k.htm
- D14P
- Upfront paid US$m 20; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1875558/000110465926122387/tmb-20260930x10q.htm
- D15
- 2026-02-11 · MASH siRNA programs | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1157601/000162828026069145/R18.htm
- D15P
- Upfront paid US$m 60; other paid US$m 4 | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1157601/000162828026069145/R18.htm
- D16
- 2026-01-12 · AMP-110 | payer or joint release (nasdaq.com) | | https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-announces-exclusive-license-agreement-nanjing-hanxin
- D16P
- Upfront paid US$m 2; other paid US$m not specified | payer filing or issuer release (nasdaq.com) | | https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-announces-exclusive-license-agreement-nanjing-hanxin
- D17
- 2026-09-03 · HMPL-A830 | licensor SEC exhibit (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1648257/000164825726000057/hcm-20260903xex99d1.htm
- D18
- 2026-07-14 · AVR-001 / HS-20118 | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1661059/000110465926123934/tm2623032-12_424b3.htm
- D18P
- Upfront paid US$m 90; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1661059/000110465926123934/tm2623032-12_424b3.htm
- D18X
- US$120m split 90/30 | payer contract exhibit (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1661059/000110465926112469/nxtc-ex10d53.htm
- D19
- 2026-10-29 · KIO-401 | payer or joint release (ir.kiorapharma.com) | | https://ir.kiorapharma.com/sec-filings/all-sec-filings/content/0001372514-26-000088/kprx-20261023.htm
- D19P
- Upfront paid US$m unverified; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1372514/000137251426000092/kprx-20260930.htm
- D19X
- $12.5m technology-transfer milestone | payer filing (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1372514/000137251426000092/kprx-20260930.htm
- D20
- 2026-09-28 · TLB-33 / MT-2990 | payer or joint release (tolerancebio.com) | | https://www.tolerancebio.com/recent-news/tolerance-bio-licenses-clinical-stage-anti-il-33-monoclonal-antibody-from-tanabe-pharma-to-expand-thymus-focused-clinical-pipeline
- D21
- 2026-08-18 · Dersimelagon / MT-7117 | licensor disclosure (us.tanabe-pharma.com) | | https://us.tanabe-pharma.com/news-and-media/press-releases/2026/tanabe-pharma-enters-into-agreement-with-leo-pharma-for-mt-7117-for-epp-and-xlp
- D22
- 2026-06-03 · Lorundrostat | payer or joint release (ir.mineralystx.com) | | https://ir.mineralystx.com/sec-filings/all-sec-filings/content/0001628280-26-040024/mlys-20260602.htm
- D22P
- Upfront paid US$m 200; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm
- D23
- 2026-04-10 · SCO-483 | licensor disclosure (scohia.com) | | https://www.scohia.com/eng/sys/news/260410en/
- D23R
- Licensor confirms upfront receipt US$m 20; other cash US$m not specified | licensor receipt (scohia.com) | | https://www.scohia.com/eng/sys/news/260410en/
- D24
- 2026-01-07 · Quizartinib | payer or joint release (genesispharma.com) | | https://www.genesispharma.com/newsroom/news/daiichi-sankyo-and-genesis-pharma-enter-exclusive-agreement-for-quizartinib-commercialization-in-central-eastern-europe/
- D25
- 2026-10-29 · HM15421 / GC1134A | payer or joint release (investors.biomarin.com) | | https://investors.biomarin.com/news/news-details/2026/BioMarin-Enters-Into-Exclusive-Worldwide-License-Agreement-With-GC-Biopharma-and-Hanmi-Pharm-for-Investigational-Next-Generation-Enzyme-Replacement-Therapy-Adding-a-Second-Potential-Treatment-for-Fabry-Disease/default.aspx
- D26
- 2026-10-14 · ADC linker and payload technology | payer or joint release (alentis.ch) | | https://alentis.ch/alentis-and-pinotbio-announce-collaboration-to-develop-next-generation-adcs-targeting-claudin-1/
- D27
- 2026-08-24 · HM17321 | licensor disclosure (hanmipharm.com) | | https://www.hanmipharm.com/about/investor-relations/press/detail-4843.hm
- D28
- 2026-06-01 · Cevidoplenib | licensor disclosure (oscotec.com) | | https://oscotec.com/archives/394656
- D28P
- Upfront paid US$m 25; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1439222/000143922226000118/agio-20260630.htm
- D29
- 2026-03-25 · ALT-B4 / Hybrozyme | licensor disclosure (en.prnasia.com) | | https://en.prnasia.com/releases/global/alteogen-enters-into-a-license-agreement-with-biogen-for-development-and-commercialization-of-hybrozyme-based-subcutaneous-biologics-526696.shtml
- D29P
- Upfront paid US$m 20; other paid US$m not specified | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260630.htm
- D30
- 2026-03-24 · Denfivontinib | payer or joint release (yatiribio.com) | | https://yatiribio.com/2026/03/24/yatiri-bio-enters-exclusive-option-to-in-license-agreement-with-oscotec-for-denfivontinib-in-aml/
- D31
- 2026-01-09 · SPiDEM degrader platform | licensor disclosure (prazertx.com) | | https://prazertx.com/pages/board/view.php?board_sid=16&category_code1=&data_sid=278&menu_code=477&page_num=&skey=&sval=
- D32
- 2026-10-05 · TLC599 | licensor disclosure (mopsov.twse.com.tw) | | https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=1&spoke_time=152833&spoke_date=20261005&co_id=7924&TYPEK=rotc
- D33
- 2026-09-16 · Extended-release tamsulosin ODT | licensor disclosure (anxo.com.tw) | | https://www.anxo.com.tw/news/view/231
- D34
- 2026-08-10 · LT1001 | licensor disclosure (mopsov.twse.com.tw) | | https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=5&spoke_time=180917&spoke_date=20260810&co_id=6535&TYPEK=otc
- D35
- 2026-06-11 · APP13007 | licensor disclosure (formosapharma.com) | | https://www.formosapharma.com/%E5%8F%B0%E6%96%B0%E8%97%A5%E5%AE%A3%E5%B8%83%E8%88%87samil-pharmaceutical-%E7%B0%BD%E7%BD%B2%E6%8E%88%E6%AC%8A%E5%8D%94%E8%AD%B0%EF%BC%8C%E6%8E%A8%E5%8B%95%E7%9C%BC%E9%83%A8%E8%A1%93%E5%BE%8C/
- D36
- 2026-02-23 · APP13007 | licensor disclosure (formosapharma.com) | | https://www.formosapharma.com/formosa-pharmaceuticals-announces-licensing-agreement-with-arrotex-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-pain-following-ocular-sur/
- D37
- 2026-01-26 · Pixavir marboxil / TG-1000 | licensor disclosure (taigenbiotech.com) | | https://www.taigenbiotech.com/en/news/detail/226
- D38
- 2026-01-12 · APP13007 | licensor disclosure (formosapharma.com) | | https://www.formosapharma.com/formosa-pharmaceuticals-announces-licensing-agreement-with-samil-pharmaceuticals-co-ltd-for-commercialization-of-clobetasol-propionate-ophthalmic-suspension-for-the-treatment-of-inflammation-and-p/
- D39
- 2026-01-08 · MMP-12 inhibitor programs | licensor disclosure (foreseepharma.com) | | https://www.foreseepharma.com/en/news/category/press_releases/foresee_pharmaceuticals_announces_global_licensing_agreement_for_mmp_12_inhibitors_with_primevera_therapeutics_llc?page=1
- D39R
- US$10m cash proceeds; NT$316.473m investing inflow; 19% equity initially valued at US$7.79m | licensor interim financial statements (foreseepharma.com) | | https://www.foreseepharma.com/uploads/images/%28%E5%A5%97%E5%8D%B0%29%E9%80%B8%E9%81%94%E7%94%9F%E6%8A%80_2026%E5%90%88%E4%BD%B5%E7%AC%AC%E4%BA%8C%E5%AD%A3_20260630_FS_AllReport_CHT.pdf
- D39X
- US$10m upfront; $214.5m regulatory + $360m sales = $574.5m milestones; $584.5m combined; 19% equity | licensor shareholder circular (foreseepharma.com) | | https://www.foreseepharma.com/uploads/images/114%E5%B9%B4%E8%82%A1%E6%9D%B1%E8%87%A8%E6%99%82%E6%9C%83%E8%AD%B0%E4%BA%8B%E6%89%8B%E5%86%8A%28%E4%B8%AD%E6%96%87%29_20251128_Final.pdf
- D40
- 2026-11-13 · ADC platform | licensor disclosure (obipharma.com) | | https://www.obipharma.com/zh-hant/news/signs-collaboration-and-license-agreement-with-novartis/
- D40X
- 2026-11-13 public announcement; $30m upfront; total potential value above $2bn | licensor MOPS filing (mopsov.twse.com.tw) | | https://mopsov.twse.com.tw/mops/web/ajax_t05st01?firstin=1&step=2&seq_no=3&spoke_time=171730&spoke_date=20261113&co_id=4174&TYPEK=otc
- D99
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000110465926086846/azn-20260630x6k.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/78003/000007800326000127/pfe-20260927.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/14272/000001427226000024/bmy-20260930.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/901832/000165495426009256/a0835b.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260930.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1438533/000143853326000077/tvtx-20260930.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1701108/000119312526458593/spro-20260930.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1875558/000110465926122387/tmb-20260930x10q.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1157601/000162828026069145/R18.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (nasdaq.com) | | https://www.nasdaq.com/press-release/amphastar-pharmaceuticals-announces-exclusive-license-agreement-nanjing-hanxin
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1661059/000110465926123934/tm2623032-12_424b3.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1933414/000193341426000144/mlys-20260930.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/1439222/000143922226000118/agio-20260630.htm
- 14 payer-confirmed rows; USD 3714.5m upfront | payer filing or issuer release (sec.gov) | | https://www.sec.gov/Archives/edgar/data/875045/000087504526000096/biib-20260630.htm